Evaluation of the efficacy and safety of Inebilizumab in the treatment of isolated aquaporin4 antibody seropositive optic neuritis: a multicenter, prospective, non-randomized, positive-controlled clinical trial

Start Date03 Feb 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT05145361

/ RecruitingEarly Phase 1

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of B001 in Subjects With Aquaporin-4 Antibody (AQP4-IgG) Positive Neuromyelitis Optic Spectrum Disorder (NMOSD)

The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positive NMOSD.

Start Date07 Apr 2022

Sponsor / Collaborator

Shanghai Pharmaceuticals Holding Co., Ltd.

NCT05540262

/ RecruitingNot ApplicableIIT

Edaravone in the Treatment of Optic Neuritis

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Start Date15 Jan 2022

Sponsor / Collaborator

First Affiliated Hospital of Guangxi Medical University

100 Clinical Results associated with AQP4-IgG positive Optic Neuritis

100 Translational Medicine associated with AQP4-IgG positive Optic Neuritis

0 Patents (Medical) associated with AQP4-IgG positive Optic Neuritis

111

Literatures (Medical) associated with AQP4-IgG positive Optic Neuritis

18 Apr 2025·International Journal of Ophthalmology

A case of post-infectious anti-myelin oligodendrocyte glycoprotein antibody-positive optic neuritis

Letter

Author: Kim, Kye-Hyung ; Son, Yu Bin ; Choi, Hee-Young ; Jeon, Hyeshin

11 Mar 2025·Neurology

Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder

Article

Author: Decombe, Rene ; Piljan, Mathilde ; Stankoff, Bruno ; Maillart, Elisabeth ; Lubetzki, Catherine ; Beigneux, Ysoline ; Dubessy, Anne-Laure ; Shor, Natalia ; Marignier, Romain

OBJECTIVESSeveral treatments have been approved for the prevention of attacks in AQP4-IgG+ neuromyelitis optica spectrum disorder (NMOSD). However, because of the rarity of the disease, little is known concerning how to switch from one treatment to another in case of lack of effectiveness or side effects. In this article, we report a severe attack in a patient with NMOSD after switching from eculizumab to satralizumab.METHODSA 44-year-old woman with NMOSD was treated with azathioprine and then rituximab, without optimal control of the disease. Eculizumab was initiated with clinical efficacy. Two years later, after the onset of rheumatoid arthritis and because of difficult venous access, a switch to satralizumab was proposed.RESULTSAfter switching, a severe attack occurred 11 weeks after the last eculizumab infusion. Severe tetraplegia was related to a new extensive cervical lesion associated with a tumefactive lesion of the corpus callosum. The patient was treated with 10 infusions of methylprednisolone and 10 plasma exchanges. Eculizumab was reintroduced 20 days after symptom onset. Three months later, mild improvement was observed.DISCUSSIONIn clinical practice, in case of intolerance or side effects, anticomplement therapy should be switched to another NMOSD treatment with caution because of a high risk of relapse.CLASSIFICATION OF EVIDENCEThis case report provides Class IV evidence that eculizumab should be stopped with caution and switched to another treatment immediately. This is a single observational study without controls.

01 Mar 2025·Journal of Neuro-Ophthalmology

Two Cases of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Double-Positive Optic Neuritis Successfully Treated With Steroid Therapy

Article

Author: Yamashiro, Kenji ; Fukuda, Ken ; Nakajima, Isana ; Fujii, Norimitsu ; Takahashi, Toshiyuki ; Masaoka, Misa ; Mizobuchi, Tomoka

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

AQP4-IgG positive Optic Neuritis

Basic Info

Related

Analysis